Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia;Wpływ fluwastatyny o powolnym uwalnianiu na Strukturȩ białkowo-lipidowa̧ błon erytrocytów i białko C-reaktywne u pacjentówz hiperlipidemia̧

Polski Merkuriusz Lekarski

Volumn 22, Issue 128, 2007, Pages 107-111

  Broncel, Marlena ^a,b,e   Balcerak, Madgalena ^a,b,e   Cieśla, Dorota ^a,b,e   Duchnowicz, Piotr ^a,c   Koter Michalak, Maria ^a,c   Sikora, Joanna ^a,d   Chojnowska Jezierska, Julita ^a,b,e  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Klinika Chorob Wewnetrznych z Oddziaem Farmakologii Klinicznej i Terapii Monitorowanej   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d Katedra Biofizyki Skazeń Środowiska ^*

^e Department of Internal Diseases with Clinical Pharmacology   (Poland)

Author keywords

C reactive protein; Erythrocyte membrane; Fluvastatin XL

Indexed keywords

C REACTIVE PROTEIN; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECT; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; REFERENCE VALUE; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; DELAYED-ACTION PREPARATIONS; ERYTHROCYTE MEMBRANE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERLIPIDEMIAS; INDOLES; LIPID METABOLISM; MALE; MIDDLE AGED; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 33947134534     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bandoh T., Sato E.F., Mitam H. i wsp.: Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol. Pharm. Bull., 2003, 26, 818-822.
2. Bartosz G., Bartosz M., Sokal A. i wsp.: Stimulation of erythrocyte membrane Mg+2ATPase activity by dinitrophenol and other membrane- disturbing agents. Biochem. Mol. Biol. Int., 1994, 34, 521-529.
3. Case C. C., Ballantyne C. M.: Statins and markers of inflammation. Curr. Atheroscler. Rep., Łóodź, 4, 42.
4. Corsini A., Jacobson T.A., Ballantyne C.M.: Fluvastatin. Clinical and safety profile. Drugs, 2004, 54, 1305-1323.
5. Dodge J.T., Mitchell C., Hanahan D.J.: Preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem., 1963, 100, 119-130.
6. Friedewald W.T., Levy R.I., Fredrickson D.S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18, 499-502.
7. + pump density. Cardiovasc. Res., 2000, 47, 329-335.
8. Guan J.Z., Murakami H., Yamato K. i wsp.: Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1. J. Atheroscler. Thromb., 2004, 11, 56-61
9. Hussein O., Schlezinger S., Rosenblat M. i wsp.: Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997, 128, 11-18.
10. Jorge P.A., Almeida E.A., Ozaki M.R. i wsp.: Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits. Arquios Brasileiros de Cardiologia, 2005, 84, 52-58.
11. Kanakaraj P., Singh M.: Influence of hypercholesterolemia on morphological and Theological characteristics of erythrocytes. Atherosclerosis, 1989, 76, 209-218.
12. Klyszejko-Stefanowicz L.: Cytobiochemia. PWN, Warszawa, 1995.
13. Koter M., Broncel M., Chojnowska-Jezierska J. i wsp.: The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type 2-hypercholeserolemia. Eur. J. Clin. Pharmacol., 2002, 58, 501-506.
14. Koter M., Franiak I., Broncel M. i wsp.: Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia. Can. J. Physiol. Pharmacol., 2003, 81, 1-8.
15. Koter M., Franiak I., Strychalska K. i wsp.: Damage to the structure of erythrocyte plasma membranes in patients with type-2 hypercholesterolemia. Int. J. Biochem. Cell Biol., 2004, 36, 205-215.
16. Kowalski J., Błaszczyk J., Olejniczak J. i wsp.: Wpływ fluwastatyny i fenofibratu na wytwarzanie reaktywnych form tlenu i peroksydacjȩ lipidów u chorych z dyslipidemia̧. Pol. Merk. Lek., 2003, 14, 279-283.
17. Lijnen P., Cells H., Fagard R.: Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J. Hypertens., 1994, 12, 59-64.
18. Lowry O.H., Rosebrough A., Ferr L. i wsp.: Protein measurement with the Folin Phenol reagent. J. Biol. Chem., 1951, 193, 265-277.
19. di Lullo L., Addesse R., Comegna C. i wsp.: Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure. Adv. Ther., 2005, 22, 601-612.
20. Miwa S., Wataha H., Omura C., Takayanagi N. i wsp.: Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients. Endocr. J., 2005, 52, 259-264.
21. Özdemirler G., Kucuk S., Orhan Y. i wsp.: Lipid and Protein oxidation in erythrocyte membrane of hypercholesterolemic subjects. Clin. Biochem., 2001, 34, 335-339.
22. Pawełezyk T., Kłoszewska I., Sobów T.: Statyny "aspiryna̧, XXI wieku"? Pol. Merk. Lek., 2005, 19, 111-114.
23. Pfafferott C., Meiselman H.J., Hochstein P.: The effect of malondialdehyde on erythrocyte deformability. Blood, 1982, 59, 12-15.
24. Pinon F., Merino J.F., Ferrer J.C. iwsp.: Plasma lipids and blood fluidity in patients with polygenic hypercholesterolemia treated with fluvastatin. Clin. Hemorheol. Microcirc., 2002, 27, 193-199.
25. Rabini R.A., Polenta M., Staffolani R.: Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes. Exp. Mol. Pathol., 1993, 59, 51-57.
26. Rodriguez-Vico F., Martinez-Cayuela M., Zafra M. F. i wsp.: A procedure for the simultaneous determination of lipid and protein in biomembranes and other biological samples. Lipids, 1991, 26, 77-80.
27. Ross R.: Atherosclerosis: an inflammatory disease. NEJM, 1999, 340, 115-126.
28. Saitta A., Castaldo M., Sardo A. i wsp.: Effects of fluvastatin treatment on red blood cell Na+ transport systems in hypercholesterolemic subjects. J. Cardiovasc. Pharmacol., 2000, 35, 376-382.
29. Simon E., Paul J.L., Atger V. i wsp.: Erythrocyte antioxidant status in asymptomatic hypercholesterolemic men. Atherosclerosis, 1998, 138, 375-381.
30. Stocks J., Dormandy T.L.: The autoxidation of human red cell lipids induced by hydrogen peroxide. Br. J. Haematol., 1971, 20, 95-111.
31. van Veldhoven P.P., Mannaeters G.P.: Inorganic and organic phosphate measurements in the nanomolar range. Anal. Biochem., 1987, 161, 45-48.
32. Yang J., Li X.P., Zhao S.P., i wsp.: The effect of different doses of fluvastatin on inflammatary markers in the early phase of acute coronary syndrome. Clin. Chim. Acta, 2006, 368, 183-187.